Diabetic retinopathy and diabetic macular edema

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 137-146

  Cohen, Steven R ^a   Gardner, Thomas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; HUMAN; MACULAR EDEMA; PATHOPHYSIOLOGY; RETINA;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947247165     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000438970     Document Type: Article

References (88)

1. The Eye Diseases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122:552-563.
2. Wilkinson-Berka JL, Miller AG: Update on the treatment of diabetic retinopathy. ScientificWorldJournal 2008; 8:98-120.
3. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26:1258-1264.
4. Bhavsar AR, Drouilhet JH, Atebara NH, et al. Diabetic Retinopathy. 2014, http://emedicine.medscape.com/article/1225122-overview#a0156.
5. Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55:2401-2411.
6. Girach A, Vignati L: Diabetic microvascular complications-can the presence of one predict the development of another? J Diabetes Complications 2006; 20:228-237.
7. The effect of intensive treatment of diabetes on the development and progression of long-Derm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
8. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group: Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122:1631-1640.
9. Harris Nwanyanwu K, Talwar N, Gardner TW, Wrobel JS, Herman WH, Stein JD: Predicting development of proliferative diabetic retinopathy. Diabetes Care 2013; 36:1562-1568.
10. Antonetti DA, Klein R, Gardner TW: Diabetic retinopathy. N Engl J Med 2012; 366:1227-1239.
11. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 2008; 105:6998-7003.
12. Kuo JZ, Wong TY, Rotter JI: Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol 2014; 132:96-107.
13. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46:4295-4301.
14. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, EURODIAB Prospective Complications Study Group: Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-Dhe EURODIAB Prospective Complications Study. Diabetologia 2005; 48:370-378.
15. Nin JW, Ferreira I, Schalkwijk CG, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009; 52:705-714.
16. Zhou J, Wang S, Xia X: Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 2012; 37:416-420.
17. Wolfensberger TJ, Hamilton AM: Diabetic retinopathy-An historical review. Semin Ophthalmol 2001; 16:2-7.
18. Bloodworth JM Jr: Diabetic retinopathy. Diabetes 1962; 11:1-22.
19. Wolter JR: Diabetic retinopathy. Am J Ophthalmol 1961; 51:1123-1141.
20. Simonsen SE: ERG in juvenile diabetics: a prognostic study; in Goldberg MF, Fine SL (eds): Symposium on the Treatment of Diabetic Retinopathy. Arlington, US Department of Health, Education and Welfare, 1969, pp 681-689.
21. Bresnick GH: Diabetic retinopathy viewed as a neurosensory disorder. Arch Ophthalmol 1986; 104:989-990.
22. Bresnick GH, Palta M: Predicting progression to severe proliferative diabetic retinopathy. Arch Ophthalmol 1987; 105:810-814.
23. Ghirlanda G, Di Leo MA, Caputo S, Cercone S, Greco AV: From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab Rev 1997; 13:15-35.
24. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102:783-791.
25. Gastinger MJ, Singh RS, Barber AJ: Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006; 47:3143-3150.
26. Barber AJ, Antonetti DA, Gardner TW: Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000; 41:3561-3568.
27. Mizutani M, Gerhardinger C, Lorenzi M: Muller cell changes in human diabetic retinopathy. Diabetes 1998; 47:445-449.
28. Puro DG: Diabetes-induced dysfunction of retinal Müller cells. Trans Am Ophthalmol Soc 2002; 100:339-352.
29. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000; 41:1971-1980.
30. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54:1559-1565.
31. Zeng HY, Green WR, Tso MO: Microglial activation in human diabetic retinopathy. Arch Ophthalmol 2008; 126:227-232.
32. Bensaoula T, Ottlecz A: Biochemical and ultrastructural studies in the neural retina and retinal pigment epithelium of STZ-diabetic rats: effect of captopril. J Ocul Pharmacol Ther 2001; 17:573-586.
33. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 1990; 108:1234-1244.
34. PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54:2188-2197.
35. Group P-D, Aiello LP, Davis MD, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113:2221-2230.
36. Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase C β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1, 392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina 2011; 31:2084-2094.
37. Sheetz MJ, Aiello LP, Davis MD, et al. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies. Invest Ophthalmol Vis Sci 2013; 54:1750-1757.
38. Greenbaum CJ: Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002; 18:192-200.
39. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005; 115:1111-1119.
40. Dana GW: Type of diabetes mellitus associated with diabetic retinitis. AMA Arch Ophthalmol 1953; 50:123-124.
41. Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 2000; 41:1153-1158.
42. Reiter CE, Sandirasegarane L, Wolpert EB, et al. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab 2003; 285:E763-E774.
43. Reiter CE, Gardner TW: Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog Retin Eye Res 2003; 22:545-562.
44. Reiter CE, Wu X, Sandirasegarane L, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006; 55:1148-1156.
45. Wilkinson-Berka JL: Diabetes and retinal vascular disorders: role of the renin-Angiotensin system. Expert Rev Mol Med 2004; 6:1-18.
46. Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G: Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2011; 7:CD008081.
47. Sim DA, Keane PA, Fung S, et al. Quantitative analysis of diabetic macular ischemia using optical coherence tomography. Invest Ophthalmol Vis Sci 2014; 55:417-423.
48. Silva PS, Cavallerano JD, Sun JK, Noble J, Aiello LM, Aiello LP: Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy. Am J Ophthalmol 2012; 154:549.e2-559.e2.
49. Wessel MM, Aaker GD, Parlitsis G, Cho M, D'Amico DJ, Kiss S: Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 2012; 32:785-791.
50. Lombardo M, Parravano M, Serrao S, Ducoli P, Stirpe M, Lombardo G: Analysis of retinal capillaries in patients with type 1 diabetes and nonproliferative diabetic retinopathy using adaptive optics imaging. Retina 2013; 33:1630-1639.
51. Dubow M, Pinhas A, Shah N, et al. Classification of human retinal microaneurysms using adaptive optics scanning light ophthalmoscope fluorescein angiography. Invest Ophthalmol Vis Sci 2014; 55:1299-1309.
52. Jackson GR, Scott IU, Quillen DA, Walter LE, Gardner TW: Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol 2012; 96:699-703.
53. Field MG, Elner VM, Puro DG, et al. Rapid, noninvasive detection of diabetes-induced retinal metabolic stress. Arch Ophthalmol 2008; 126:934-938.
54. Gardner TW, Jackson GR, Quillen DA, Scott IU: Diabetic retinopathy: translating discoveries to treatments; in Greenbaum C, Harrison LC (eds): Diabetes: Translating Discoveries into Practice. New York, Informa, 2008, pp 173-192.
55. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E: Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 2000; 78:374-385.
56. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102:647-661.
57. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44:156-163.
58. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88:583-600.
59. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98:766-785.
60. Mohamed Q, Gillies MC, Wong TY: Management of diabetic retinopathy: a systematic review. JAMA 2007; 298:902-916.
61. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103:1796-1806.
62. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS: Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013; 4:151-169.
63. Miller JW, Le Couter J, Strauss EC, Ferrara N: Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 2013; 120:106-114.
64. Brown DM, Nguyen QD, Marcus DM, et al. Long-Derm outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120:2013-2022.
65. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064.e35-1077.e35.
66. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119:2312-2318.
67. Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for Edema of the Macula in Diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013; 131:139-145.
68. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614.
69. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118:615-625.
70. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130:972-979.
71. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013; 156:502.e2-510.e2.
72. Moradi A, Sepah YJ, Sadiq MA, et al. Vascular endothelial growth factor Trap-Eye (aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4:303-309.
73. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372:1193-1203.
74. Bressler SB, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013; 131:1033-1040.
75. Ahn J, Woo SJ, Chung H, Park KH: The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011; 118:2218-2226.
76. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47(suppl 2):S253-S262.
77. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1447-1449, 1449.e1-1449.e10.
78. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120:1843-1851.
79. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119:2125-2132.
80. Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117:1087.e3-1093.e3.
81. Shamsi HN, Masaud JS, Ghazi NG: Diabetic macular edema: new promising therapies. World J Diabetes 2013; 4:324-338.
82. Diaz-Llopis M, Udaondo P, Millan JM, Arevalo JF: Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. World J Diabetes 2013; 4:319-323.
83. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012; 367:606-615.
84. Gardner TW, Antonetti DA: Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep 2008; 8:263-269.
85. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R: Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86:385-389.
86. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860-1867.
87. Blankenship GW: Fifteen-year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Trans Am Ophthalmol Soc 1990; 88:179-185; discussion 85-89.
88. Aiello LP, DCCT/EDIC Research Group: Diabetic retinopathy and other ocular findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014; 37:17-23.